Geert Kersten - CEL SCI Chief Executive Officer, Treasurer, Director
| CVM Stock | USD 0.69 0.05 6.76% |
CEO
Mr. Geert R. Kersten, Esq., is Chief Executive Officer, Treasurer, Director of CELSCI Corporationrationration. Mr. Kersten was with CELSCI since 1987. He was involved in the pioneering field of cancer immunotherapy for over two decades and has successfully steered CELSCI through many challenging cycles in the biotechnology industry. Mr. Kersten also provides CELSCI with significant expertise in the fields of finance and law and has a unique vision of how CELSCI Multikine product could potentially change the way cancer is treated. Prior to joining CELSCI, Mr. Kersten worked at the law firm of Finley Kumble and worked at Source Capital, an investment banking firm located in McLean, VA. He is a native of Germany, graduated from high school in England, and completed his studies in the US. Mr. Kersten received his Undergraduate Degree in Accounting and an M.B.A. from George Washington University and a law degree from American University in Washington, DC. Mr. Kerstens experience overseeing the financing and research and development of CELSCI for over 25 years qualifies him to continue to serve on CELSCIs board of directors. Mr. Kersten is also the inventor of a patent on the potential use of Multikine in managing cholesterol. since 1995.
| Age | 60 |
| Tenure | 29 years |
| Professional Marks | MBA |
| Address | 8229 Boone Boulevard, Vienna, VA, United States, 22182 |
| Phone | 703 506 9460 |
| Web | https://cel-sci.com |
Geert Kersten Latest Insider Activity
Tracking and analyzing the buying and selling activities of Geert Kersten against CEL SCI stock is an integral part of due diligence when investing in CEL SCI. Geert Kersten insider activity provides valuable insight into whether CEL SCI is net buyers or sellers over its current business cycle. Note, CEL SCI insiders must abide by specific rules, including filing SEC forms every time they buy or sell CEL SCI'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Geert Kersten over three months ago Acquisition by Geert Kersten of 4461 shares of CEL SCI at 1.16 subject to Rule 16b-3 | ||
Geert Kersten over six months ago Acquisition by Geert Kersten of 250000 shares of CEL SCI at 1.5 subject to Rule 16b-3 | ||
Geert Kersten over six months ago Acquisition by Geert Kersten of 2709 shares of CEL SCI at 1.91 subject to Rule 16b-3 | ||
Geert Kersten over six months ago Acquisition by Geert Kersten of 966 shares of CEL SCI at 4.5 subject to Rule 16b-3 |
CEL SCI Management Efficiency
The company has Return on Asset of (0.6141) % which means that on every $100 spent on assets, it lost $0.6141. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.502) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of December 2024, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Total Assets are very stable compared to the past year. As of the 16th of December 2024, Non Current Assets Total is likely to grow to about 28.5 M, while Return On Tangible Assets are likely to drop (1.01).Similar Executives
| Found 2 records | CEO Age | ||
| Spiro Rombotis | Cyclacel Pharmaceuticals | 65 | |
| Jon Stonehouse | BioCryst Pharmaceuticals | 63 | |
Management Performance
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 |
CEL SCI Corp Leadership Team
Elected by the shareholders, the CEL SCI's board of directors comprises two types of representatives: CEL SCI inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CEL. The board's role is to monitor CEL SCI's management team and ensure that shareholders' interests are well served. CEL SCI's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CEL SCI's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Young, Independent Director | ||
| Giovanni MD, Acting Officer | ||
| Geert Kersten, Chief Executive Officer, Treasurer, Director | ||
| Robert Watson, Independent Director | ||
| John Cipriano, Senior Vice President - Regulatory Affairs | ||
| Patricia Prichep, Senior Vice President - Operations, Corporate Secretary | ||
| Bruno Baillavoine, Independent Director | ||
| Geert Esq, Treasurer Officer | ||
| Eyal Talor, Chief Scientific Officer | ||
| Daniel Zimmerman, Senior Vice President - Research, Cellular Immunology |
CEL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is CEL SCI a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.5 | ||||
| Return On Asset | -0.61 | ||||
| Current Valuation | 55.77 M | ||||
| Shares Outstanding | 63.81 M | ||||
| Shares Owned By Insiders | 2.91 % | ||||
| Shares Owned By Institutions | 10.46 % | ||||
| Number Of Shares Shorted | 4.43 M | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 5.20 X | ||||
| Price To Sales | 11,797 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.